Oncoclínicas do Brasil Serviços Médicos Future Growth
Future criteria checks 4/6
Oncoclínicas do Brasil Serviços Médicos is forecast to grow earnings and revenue by 36.9% and 12.6% per annum respectively. EPS is expected to grow by 43.8% per annum. Return on equity is forecast to be 10.3% in 3 years.
Key information
36.9%
Earnings growth rate
43.8%
EPS growth rate
| Healthcare earnings growth | 28.1% |
| Revenue growth rate | 12.6% |
| Future return on equity | 10.3% |
| Analyst coverage | Good |
| Last updated | 12 Sep 2024 |
Recent future growth updates
Recent updates
Here's What Analysts Are Forecasting For Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3) After Its Second-Quarter Results
Aug 15
Oncoclínicas do Brasil Serviços Médicos (BVMF:ONCO3) Takes On Some Risk With Its Use Of Debt
Aug 13Earnings Tell The Story For Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3) As Its Stock Soars 27%
Jul 16Is Now An Opportune Moment To Examine Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3)?
Jul 03Investors Appear Satisfied With Oncoclínicas do Brasil Serviços Médicos S.A.'s (BVMF:ONCO3) Prospects As Shares Rocket 25%
Jun 01Oncoclínicas do Brasil Serviços Médicos S.A.'s (BVMF:ONCO3) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Apr 17Oncoclínicas do Brasil Serviços Médicos' (BVMF:ONCO3) Earnings Are Weaker Than They Seem
Apr 03Oncoclínicas do Brasil Serviços Médicos (BVMF:ONCO3) Has A Somewhat Strained Balance Sheet
Mar 11What Does Oncoclínicas do Brasil Serviços Médicos S.A.'s (BVMF:ONCO3) Share Price Indicate?
Feb 17It's A Story Of Risk Vs Reward With Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3)
Dec 08Why Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3) Could Be Worth Watching
Nov 06Is Now The Time To Put Oncoclínicas do Brasil Serviços Médicos (BVMF:ONCO3) On Your Watchlist?
Sep 11Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3) Just Reported Earnings, And Analysts Cut Their Target Price
Apr 03Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 8,307 | 550 | 406 | N/A | 7 |
| 12/31/2025 | 7,455 | 432 | 310 | N/A | 9 |
| 12/31/2024 | 6,487 | 202 | 75 | N/A | 8 |
| 6/30/2024 | 5,862 | 193 | -614 | -310 | N/A |
| 3/31/2024 | 5,654 | 211 | -256 | 62 | N/A |
| 12/31/2023 | 5,489 | 224 | -363 | -52 | N/A |
| 9/30/2023 | 5,271 | 219 | -33 | 285 | N/A |
| 6/30/2023 | 5,033 | 145 | -249 | 78 | N/A |
| 3/31/2023 | 4,574 | 91 | -642 | -346 | N/A |
| 12/31/2022 | 4,088 | 46 | -572 | -272 | N/A |
| 9/30/2022 | 3,640 | -10 | -740 | -378 | N/A |
| 6/30/2022 | 3,155 | 105 | -593 | -324 | N/A |
| 3/31/2022 | 2,895 | -67 | -415 | -185 | N/A |
| 12/31/2021 | 2,702 | -47 | -211 | -9 | N/A |
| 9/30/2021 | 2,509 | -203 | -138 | 27 | N/A |
| 6/30/2021 | 2,354 | -334 | -128 | 9 | N/A |
| 3/31/2021 | 2,182 | -145 | -17 | 154 | N/A |
| 12/31/2020 | 2,035 | -158 | -19 | 186 | N/A |
| 12/31/2019 | 1,690 | -20 | -93 | 97 | N/A |
| 12/31/2018 | 1,051 | -17 | -296 | -18 | N/A |
| 12/31/2017 | 792 | 3 | N/A | 135 | N/A |
| 12/31/2016 | 595 | -25 | N/A | -21 | N/A |
| 12/31/2015 | 458 | -25 | N/A | -3 | N/A |
| 12/31/2014 | 359 | -22 | N/A | 9 | N/A |
| 12/31/2013 | 269 | 21 | N/A | 7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ONCO3's forecast earnings growth (36.9% per year) is above the savings rate (10.1%).
Earnings vs Market: ONCO3's earnings (36.9% per year) are forecast to grow faster than the BR market (14.1% per year).
High Growth Earnings: ONCO3's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ONCO3's revenue (12.6% per year) is forecast to grow faster than the BR market (7.9% per year).
High Growth Revenue: ONCO3's revenue (12.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ONCO3's Return on Equity is forecast to be low in 3 years time (10.3%).